Is PSTV or HYPR more profitable?

Hyperfine has a net margin of -226.88% compared to Plus Therapeutics' net margin of -230.24%. Hyperfine's return on equity of -98.83% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Plus Therapeutics -230.24% -198.48% -73.13% Hyperfine -226.88% -98.83% -67.09%

Does the media refer more to PSTV or HYPR?

In the previous week, Plus Therapeutics had 1 more articles in the media than Hyperfine. MarketBeat recorded 2 mentions for Plus Therapeutics and 1 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.94 beat Plus Therapeutics' score of 0.00 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperfine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is PSTV or HSDT more profitable?

Plus Therapeutics has a net margin of -230.24% compared to Solana's net margin of -1,427.15%. Solana's return on equity of -67.57% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Plus Therapeutics -230.24% -198.48% -73.13% Solana -1,427.15% -67.57% -24.09%

Does the media refer more to PSTV or SNWV?

In the previous week, Sanuwave Health had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 3 mentions for Sanuwave Health and 2 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 equaled Sanuwave Health'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanuwave Health 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PSTV or PYPD more profitable?

PolyPid has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets Plus Therapeutics -230.24% -198.48% -73.13% PolyPid N/A -241.96% -126.91%

Does the media favor PSTV or PYPD?

In the previous week, Plus Therapeutics had 1 more articles in the media than PolyPid. MarketBeat recorded 2 mentions for Plus Therapeutics and 1 mentions for PolyPid. PolyPid's average media sentiment score of 1.93 beat Plus Therapeutics' score of 0.00 indicating that PolyPid is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PolyPid 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Plus Therapeutics (PSTV) Competitors

$3.83 +0.09 (+2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$3.79 -0.04 (-1.07%)

As of 07:56 PM Eastern

Compare

PSTV vs. LAKE, HYPR, HSDT, SNWV, and PYPD

Should you buy Plus Therapeutics stock or one of its competitors? MarketBeat compares Plus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Plus Therapeutics include Lakeland Industries (LAKE), Hyperfine (HYPR), Solana (HSDT), Sanuwave Health (SNWV), and PolyPid (PYPD). These companies are all part of the "medical equipment" industry.

How does Plus Therapeutics compare to Lakeland Industries?

Plus Therapeutics (NASDAQ:PSTV) and Lakeland Industries (NASDAQ:LAKE) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 71.7% of Lakeland Industries shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 3.4% of Lakeland Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Plus Therapeutics had 2 more articles in the media than Lakeland Industries. MarketBeat recorded 2 mentions for Plus Therapeutics and 0 mentions for Lakeland Industries. Plus Therapeutics' average media sentiment score of 0.00 equaled Lakeland Industries'average media sentiment score.

Company	Overall Sentiment
Plus Therapeutics	Neutral
Lakeland Industries	Neutral

Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Lakeland Industries has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Plus Therapeutics presently has a consensus target price of $56.40, indicating a potential upside of 1,372.58%. Lakeland Industries has a consensus target price of $16.00, indicating a potential upside of 39.37%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Plus Therapeutics is more favorable than Lakeland Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lakeland Industries	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Lakeland Industries has a net margin of -10.87% compared to Plus Therapeutics' net margin of -230.24%. Lakeland Industries' return on equity of -6.64% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Lakeland Industries	-10.87%	-6.64%	-4.13%

Plus Therapeutics has higher earnings, but lower revenue than Lakeland Industries. Lakeland Industries is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.06	-$22.39M	-$2.30	N/A
Lakeland Industries	$192.65M	0.59	-$25.31M	-$2.13	N/A

Summary

Lakeland Industries beats Plus Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Plus Therapeutics compare to Hyperfine?

Plus Therapeutics (NASDAQ:PSTV) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Hyperfine has a net margin of -226.88% compared to Plus Therapeutics' net margin of -230.24%. Hyperfine's return on equity of -98.83% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Hyperfine	-226.88%	-98.83%	-67.09%

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 26.3% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

In the previous week, Plus Therapeutics had 1 more articles in the media than Hyperfine. MarketBeat recorded 2 mentions for Plus Therapeutics and 1 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.94 beat Plus Therapeutics' score of 0.00 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperfine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Plus Therapeutics currently has a consensus price target of $56.40, indicating a potential upside of 1,372.58%. Hyperfine has a consensus price target of $1.78, indicating a potential upside of 82.25%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Plus Therapeutics is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Plus Therapeutics has higher earnings, but lower revenue than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.06	-$22.39M	-$2.30	N/A
Hyperfine	$11.40M	8.52	-$35.57M	-$0.41	N/A

Summary

Hyperfine beats Plus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Plus Therapeutics compare to Solana?

Plus Therapeutics (NASDAQ:PSTV) and Solana (NASDAQ:HSDT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Plus Therapeutics has a net margin of -230.24% compared to Solana's net margin of -1,427.15%. Solana's return on equity of -67.57% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Solana	-1,427.15%	-67.57%	-24.09%

Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Solana has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Plus Therapeutics presently has a consensus target price of $56.40, indicating a potential upside of 1,372.58%. Solana has a consensus target price of $3.50, indicating a potential upside of 93.37%. Given Plus Therapeutics' higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Solana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 18.6% of Solana shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 14.4% of Solana shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Plus Therapeutics has higher earnings, but lower revenue than Solana. Plus Therapeutics is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.06	-$22.39M	-$2.30	N/A
Solana	$6.02M	17.56	-$40.89M	-$109.67	N/A

In the previous week, Plus Therapeutics had 2 more articles in the media than Solana. MarketBeat recorded 2 mentions for Plus Therapeutics and 0 mentions for Solana. Plus Therapeutics' average media sentiment score of 0.00 equaled Solana'saverage media sentiment score.

Company	Overall Sentiment
Plus Therapeutics	Neutral
Solana	Neutral

Summary

Solana beats Plus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Plus Therapeutics compare to Sanuwave Health?

Plus Therapeutics (NASDAQ:PSTV) and Sanuwave Health (NASDAQ:SNWV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Sanuwave Health has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.06	-$22.39M	-$2.30	N/A
Sanuwave Health	$44.05M	1.25	$11.81M	$0.33	19.39

Plus Therapeutics currently has a consensus price target of $56.40, indicating a potential upside of 1,372.58%. Sanuwave Health has a consensus price target of $51.00, indicating a potential upside of 696.88%. Given Plus Therapeutics' higher possible upside, equities analysts plainly believe Plus Therapeutics is more favorable than Sanuwave Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Sanuwave Health has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Sanuwave Health has a net margin of 35.96% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Sanuwave Health	35.96%	-450.56%	44.87%

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 14.4% of Sanuwave Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Sanuwave Health had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 3 mentions for Sanuwave Health and 2 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 equaled Sanuwave Health'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanuwave Health	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sanuwave Health beats Plus Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Plus Therapeutics compare to PolyPid?

Plus Therapeutics (NASDAQ:PSTV) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Plus Therapeutics currently has a consensus price target of $56.40, indicating a potential upside of 1,372.58%. PolyPid has a consensus price target of $11.67, indicating a potential upside of 126.54%. Given Plus Therapeutics' higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Plus Therapeutics had 1 more articles in the media than PolyPid. MarketBeat recorded 2 mentions for Plus Therapeutics and 1 mentions for PolyPid. PolyPid's average media sentiment score of 1.93 beat Plus Therapeutics' score of 0.00 indicating that PolyPid is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Plus Therapeutics has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.06	-$22.39M	-$2.30	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

PolyPid has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
PolyPid	N/A	-241.96%	-126.91%

Summary

Plus Therapeutics beats PolyPid on 7 of the 13 factors compared between the two stocks.

Get Plus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSTV vs. The Competition

Export

Metric	Plus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$25.75M	$3.07B	$6.90B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-1.67	20.20	27.10	23.94
Price / Sales	5.06	340.68	517.51	91.92
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	5.32	4.20	10.66	6.14
Net Income	-$22.39M	$65.94M	$3.60B	$331.74M
7 Day Performance	-8.15%	-3.04%	-1.51%	-1.72%
1 Month Performance	-8.81%	-1.30%	1.11%	-1.44%
1 Year Performance	-58.76%	16.06%	23.77%	16.97%

Plus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSTV Plus Therapeutics	2.2358 of 5 stars	$3.83 +2.4%	$56.40 +1,372.6%	-59.7%	$25.75M	$5.21M	N/A	20
LAKE Lakeland Industries	2.2608 of 5 stars	$11.00 -0.3%	$16.00 +45.5%	-18.6%	$108.86M	$192.65M	N/A	2,600
HYPR Hyperfine	3.282 of 5 stars	$1.05 -3.7%	$1.78 +69.8%	+1.2%	$108.21M	$11.40M	N/A	190	Positive News
HSDT Solana	3.1328 of 5 stars	$1.71 -2.3%	$3.50 +104.7%	-81.1%	$102.18M	$6.02M	N/A	30
SNWV Sanuwave Health	2.5326 of 5 stars	$11.26 -3.6%	$51.00 +352.9%	-83.7%	$100.44M	$44.05M	34.12	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSTV) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Plus Therapeutics (PSTV) Competitors

PSTV vs. LAKE, HYPR, HSDT, SNWV, and PYPD

How does Plus Therapeutics compare to Lakeland Industries?

Summary

How does Plus Therapeutics compare to Hyperfine?

Summary

How does Plus Therapeutics compare to Solana?

Summary

How does Plus Therapeutics compare to Sanuwave Health?

Summary

How does Plus Therapeutics compare to PolyPid?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Plus Therapeutics (PSTV) Competitors

PSTV vs. LAKE, HYPR, HSDT, SNWV, and PYPD

How does Plus Therapeutics compare to Lakeland Industries?

Do insiders and institutionals have more ownership in PSTV or LAKE?

Does the media refer more to PSTV or LAKE?

Which has more volatility & risk, PSTV or LAKE?

Do analysts rate PSTV or LAKE?

Is PSTV or LAKE more profitable?

Which has stronger valuation & earnings, PSTV or LAKE?

Summary

How does Plus Therapeutics compare to Hyperfine?

Is PSTV or HYPR more profitable?

Do institutionals & insiders have more ownership in PSTV or HYPR?

Which has more volatility and risk, PSTV or HYPR?

Does the media refer more to PSTV or HYPR?

Do analysts rate PSTV or HYPR?

Which has better earnings and valuation, PSTV or HYPR?

Summary

How does Plus Therapeutics compare to Solana?

Is PSTV or HSDT more profitable?

Which has more risk & volatility, PSTV or HSDT?

Do analysts rate PSTV or HSDT?

Do institutionals and insiders have more ownership in PSTV or HSDT?

Which has higher valuation and earnings, PSTV or HSDT?

Does the media refer more to PSTV or HSDT?

Summary

How does Plus Therapeutics compare to Sanuwave Health?

Which has preferable earnings & valuation, PSTV or SNWV?

Do analysts recommend PSTV or SNWV?

Which has more volatility & risk, PSTV or SNWV?

Is PSTV or SNWV more profitable?

Do insiders and institutionals have more ownership in PSTV or SNWV?

Does the media refer more to PSTV or SNWV?

Summary

How does Plus Therapeutics compare to PolyPid?

Which has more volatility and risk, PSTV or PYPD?

Do analysts recommend PSTV or PYPD?

Do insiders & institutionals believe in PSTV or PYPD?

Does the media favor PSTV or PYPD?

Which has higher valuation & earnings, PSTV or PYPD?

Is PSTV or PYPD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools